LR23 Stock Overview
Provides psychedelic-assisted psychotherapy products and services in Canada and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Numinus Wellness Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.024 |
| 52 Week High | CA$0.086 |
| 52 Week Low | CA$0.021 |
| Beta | 1.54 |
| 11 Month Change | 15.61% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -94.44% |
| 5 Year Change | n/a |
| Change since IPO | -96.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| LR23 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -57.5% | -5.0% | -1.3% |
| 1Y | n/a | -22.0% | 7.4% |
Return vs Industry: Insufficient data to determine how LR23 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LR23 performed against the German Market.
Price Volatility
| LR23 volatility | |
|---|---|
| LR23 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LR23's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine LR23's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1964 | n/a | Payton Nyquvest | www.numinus.com |
Numinus Wellness Inc. provides psychedelic-assisted psychotherapy products and services in Canada and the United States. The company operates through Clinical Research Operations, Canadian Clinic Network, and U.S Clinic Network segments. The Clinical Research Operations segment offers clinical research management services to academic institutions and biotechnology companies.
Numinus Wellness Inc. Fundamentals Summary
| LR23 fundamental statistics | |
|---|---|
| Market cap | €11.01m |
| Earnings (TTM) | -€17.42m |
| Revenue (TTM) | €15.35m |
0.7x
P/S Ratio-0.6x
P/E RatioIs LR23 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LR23 income statement (TTM) | |
|---|---|
| Revenue | CA$22.48m |
| Cost of Revenue | CA$15.68m |
| Gross Profit | CA$6.80m |
| Other Expenses | CA$32.31m |
| Earnings | -CA$25.51m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 30.27% |
| Net Profit Margin | -113.45% |
| Debt/Equity Ratio | 35.4% |
How did LR23 perform over the long term?
See historical performance and comparison